A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.
Physiologically based pharmacokinetic modeling provides important capabilities for improving the reliability of the extrapolations across dose, species, and exposure route that are generally required in chemical risk assessment regardless of the toxic end point being considered. Recently, there has been an increasing focus on harmonization of the cancer and noncancer risk assessment approaches used by regulatory agencies. Although the specific details of applying pharmacokinetic modeling within these two paradigms may differ, it is possible to identify important elements common to both. These elements expand on a four-part framework for describing the development of toxicity: a) exposure, b) tissue dosimetry/pharmacokinetics, c) toxicity process/pharmacodynamics, and d) response. The middle two components constitute the mode of action. In particular, the approach described in this paper provides a common template for incorporating pharmacokinetic modeling to estimate tissue dosimetry into chemical risk assessment, whether for cancer or noncancer end points. Chemical risk assessments typically depend upon comparisons across species that often simplify to ratios reflecting the differences. In this paper we describe the uses of this ratio concept and discuss the advantages of a pharmacokinetic-based approach as compared to the use of default dosimetry.
Clewell
Harvey J
HJ
Environ International Corp., Ruston, Louisiana 71270, USA. hclewell@environcorp.com
Andersen
Melvin E
ME
Barton
Hugh A
HA
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008962:Models, Theoretical; D009369:Neoplasms / Q000139:chemically induced*; D009374:Neoplasms, Experimental; D010599:Pharmacokinetics; D018570:Risk Assessment; D015262:Xenobiotics / Q000009:adverse effects* / Q000493:pharmacokinetics*
D015262:Xenobiotics